GSK has agreed to acquire clinical-stage biotechnology company Nuvalent for approximately $10.6 billion, strengthening its oncology portfolio with a trio of targeted lung cancer therapies and expanding its presence in precision medicine.
The acquisition aligns with GSK’s strategy of acquiring assets that address significant unmet medical needs through validated biological targets and improved treatment profiles. The transaction brings three promising non-small cell lung cancer (NSCLC) programs under GSK’s umbrella, including two late-stage drug candidates that could reach the market later this year pending regulatory approval.
At the center of the deal are zidesamtinib (NVL-520) and neladalkib (NVL-655), next-generation targeted therapies designed to treat patients with ROS1-positive and ALK-positive NSCLC, respectively. Both investigational medicines have received Breakthrough Therapy and Orphan Drug designations from the U.S. Food and Drug Administration (FDA), highlighting their potential to address serious conditions with limited treatment options.
The FDA is currently reviewing both therapies, with regulatory decisions expected on September 18, 2026, for zidesamtinib and November 27, 2026, for neladalkib. If approved, GSK expects both products to launch in 2026 and believes they have the potential to achieve blockbuster sales.
The acquisition also includes NVL-330, a highly selective HER2 inhibitor currently being evaluated in Phase I clinical trials for HER2-altered NSCLC. In addition, GSK will gain access to Nuvalent’s broader preclinical pipeline, which includes several targeted oncology programs developed through the company’s expertise in structure-based drug design and precision medicine.
According to GSK Chief Executive Officer Luke Miels, the acquisition represents a significant opportunity to strengthen the company’s oncology business while providing patients with improved treatment options. He noted that both lead assets have demonstrated the potential to overcome efficacy and tolerability challenges associated with existing therapies.
Recent clinical data presented at major scientific meetings, including the International Association for the Study of Lung Cancer (IASLC) World Conference on Lung Cancer and the American Society of Clinical Oncology (ASCO) Annual Meeting, highlighted encouraging efficacy and safety results for both zidesamtinib and neladalkib. Researchers reported durable responses, enhanced penetration into the central nervous system, and broad activity against resistance mutations commonly associated with disease progression.
ROS1- and ALK-altered NSCLC are relatively rare forms of lung cancer that often affect younger, non-smoking adults between the ages of 40 and 50. Despite advances in targeted treatments, many patients eventually develop resistance to currently available therapies, creating demand for newer, more effective options.
Nuvalent Chief Executive Officer James Porter said the company’s focus since its founding has been to develop best-in-class kinase inhibitors using advanced chemistry and deep biological insights. He added that GSK’s global commercial infrastructure and oncology expertise will help maximize the impact of Nuvalent’s pipeline and accelerate access for patients worldwide.
For GSK, the acquisition is expected to provide near-term growth opportunities and contribute to earnings beginning in 2027. The deal also strengthens the company’s broader lung cancer strategy, complementing existing oncology programs, including its Phase III B7-H3-targeted antibody-drug conjugate, Ris-Rez.
The transaction underscores the growing importance of precision oncology and targeted therapies in modern cancer treatment, as major pharmaceutical companies continue investing heavily in innovative medicines designed to improve outcomes while reducing treatment-related side effects.